Skip to main content

Novartis Oncology

2022 Breast Cancer Guide to Patient Support Services

Novartis Oncology’s Patient Assistance Now Oncology

Novartis PANO
800-282-7630
Patient Assistance Foundation

Novartis Oncology provides a full range of patient support services through Novartis Patient Assistance Now Oncology (PANO). A list of Novartis Oncology breast cancer medications and their related assistance programs is provided in the Table.

Novartis PANO

Novartis PANO offers insurance benefit verification, information about financial assistance options, patient support counselors, patient navigators, and dedicated case managers who will assist patients in identifying which Novartis Oncology patient support programs they are eligible to receive, including the Novartis Oncology Universal Co-pay Program, free trial programs, and the Novartis Patient Assistance Foundation. To enroll, your patient will complete their portion of the PANO Service Request Form (SRF) online; once their portion is complete, the prescribing physician can complete their portion of the SRF. Click here to learn more or to enroll your patient in PANO.

Novartis also offers drug-specific programs for several medications, including Kisqali Care.

Novartis Oncology Universal Co-pay Program

Enrollment requirements for this program vary by drug. Patients may be eligible for this program if they:

  • Have private/commercial health insurance that covers the cost of the prescribed Novartis medicine
  • Do not participate in Medicare, Medicaid, TRICARE, Veterans Affairs, Department of Defense, or any other federal or state healthcare program
  • Are a resident of the United States or Puerto Rico.

Click here to learn more or to enroll your patient in the Universal Co-pay Assistance Program, or call 877-577-7756.

Novartis Patient Assistance Foundation

The Novartis Patient Assistance Foundation (NPAF) provides assistance to uninsured and underinsured patients. Not all Novartis Oncology medicines are currently supported by NPAF. Patients may be eligible if they:

  • Are experiencing financial hardship and/or have no third-party insurance coverage
  • Reside in the United States
  • Have an income that meets the financial eligibility requirements
  • Have limited or no prescription coverage.

Click here to learn more or call 800-277-2254.

Kisqali Care

Kisqali Care is a PANO program that can provide copay assistance, free trials of Kisqali, a patient starter kit, and other helpful information and resources. Patients can enroll in Kisqali Care online or by calling 800-282-7630.

TABLE Novartis Breast Cancer Drugs

Drugs
Indications
Patient support programs
Drug
Afinitor (everolimus) tablets/Afinitor Disperz (everolimus tablets for oral suspension)
Indications
Postmenopausal women with advanced HR-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole
Patient support programs
Drug
Kisqali (ribociclib) tablets
Indications
HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy, in combination with an aromatase inhibitor; postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or after disease progression on endocrine therapy, in combination with fulvestrant
Patient support programs
Drug
Piqray (alpelisib)
Indications
Treatment, in combination with fulvestrant, of postmenopausal women, and men, with HR-positive, HER2-negative, advanced or metastatic breast cancer and PIK3CA mutation, as detected by an FDA-approved test, that is progressing during or after an endocrine-based regimen
Patient support programs
Drug
Tykerb (lapatinib)
Indications
Patient support programs
HR indicates hormone receptor.

Tykerb (lapatinib) Indications

In combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab; in combination with letrozole for the treatment of postmenopausal women with HR-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated